keyword
MENU ▼
Read by QxMD icon Read
search

Risedronate

keyword
https://www.readbyqxmd.com/read/28201994/risedronate-therapy-in-patients-with-mild-to-moderate-chronic-kidney-disease-with-osteoporosis-post-hoc-analysis-of-data-from-the-risedronate-phase-iii-clinical-trials
#1
Takashi Shigematsu, Ryoichi Muraoka, Toshitsugu Sugimoto, Yoshiki Nishizawa
BACKGROUND: The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from three risedronate Japanese phase III trials. The clinical effect of risedronate therapy was evaluated in CKD patients with osteoporosis. METHODS: The Japanese clinical trials involved 852 subjects who received risedronate (2.5 mg once daily or 17.5 mg once weekly) and whose estimated glomerular filtration rate (eGFR) were calculable and at ≥ 30 mL/min...
February 15, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28123122/-evidence-for-positive-effects-of-long-term-bisphosphonate-administration
#2
Hiroshi Hagino
Long-term treatment studies on the use of bisphosphonate(BP)for more than 5 years have been reported for alendronate, risedronate, and zoledronic acid. Bone mineral density(BMD)increases over the long term;however, a large increase has been observed over a 2 to 3 year period after initiation of BP treatment followed by gradual BMD increase and achieving a state of stability. After an initial reduction, the levels of bone remodeling markers remained stable within the premenopausal range during long-term BP treatment...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28117876/interventions-to-prevent-and-treat-corticosteroid-induced-osteoporosis-and-prevent-osteoporotic-fractures-in-duchenne-muscular-dystrophy
#3
REVIEW
Jennifer M Bell, Michael D Shields, Janet Watters, Alistair Hamilton, Timothy Beringer, Mark Elliott, Rosaline Quinlivan, Sandya Tirupathi, Bronagh Blackwood
BACKGROUND: Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD...
January 24, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28069980/editor-response-retraction-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-reply-from-the-authors
#4
COMMENT
https://www.readbyqxmd.com/read/28069979/letter-re-retraction-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-reply-from-the-authors
#5
COMMENT
https://www.readbyqxmd.com/read/28049945/inflammatory-effects-of-nitrogen-containing-bisphosphonates-n-bps-modulation-by-non-n-bps
#6
Kazuhiro Shima, Masahiro Tsuchiya, Takefumi Oizumi, Teruko Takano-Yamamoto, Shunji Sugawara, Yasuo Endo
Bisphosphonates (BPs) are used against diseases with enhanced bone resorption. Those classed as nitrogen-containing BPs (N-BPs) exhibit much stronger anti-bone-resorptive effects than non-nitrogen-containing BPs (non-N-BPs). However, N-BPs carry the risk of inflammatory/necrotic side effects. Depending on their side-chains, BPs are divided structurally into cyclic and non-cyclic types. We previously found in mice that etidronate and clodronate (both non-cyclic non-N-BPs) could reduce the inflammatory effects of all three N-BPs tested (cyclic and non-cyclic types), possibly by inhibiting their entry into soft-tissue cells via SLC20 and/or SLC34 phosphate transporters...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28019683/effect-of-teriparatide-or-risedronate-in-elderly-patients-with-a-recent-pertrochanteric-hip-fracture-final-results-of-a-78-week-randomized-clinical-trial
#7
Jorge Malouf-Sierra, Umberto Tarantino, Pedro A García-Hernández, Costantino Corradini, Søren Overgaard, Jan J Stepan, Lars Borris, Eric Lespessailles, Frede Frihagen, Kyriakos Papavasiliou, Helmut Petto, Per Aspenberg, José Ramón Caeiro, Fernando Marin
We present final results of a study comparing teriparatide 20 µg QD with risedronate 35 mg QW started within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T-score ≤-2.0 and 25OHD >9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (short form-36), radiology outcomes, and safety...
December 26, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/27933174/a-case-of-hepatitis-c-associated-osteosclerosis-accelerated-bone-turnover-controlled-by-pulse-steroid-therapy
#8
Nobuhiro Miyamura, Shuhei Nishida, Mina Itasaka, Hirofumi Matsuda, Takeshi Ohtou, Yasuhiro Yamaguchi, Daisuke Inaba, Sadahiro Tamiya, Tetsuo Nakano
: Hepatitis C-associated osteosclerosis (HCAO), a very rare disorder in which an extremely rapid bone turnover occurs and results in osteosclerosis, was acknowledged in 1990s as a new clinical entity with the unique bone disorder and definite link to chronic type C hepatitis, although the pathogenesis still remains unknown. Affected patients suffer from excruciating deep bone pains. We report the 19th case of HCAO with diagnosis confirmed by bone biopsy, and treated initially with a bisphosphonate, next with corticosteroids and finally with direct acting antivirals (DAA: sofosbuvir and ribavirin) for HCV infection...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27900428/relationship-between-baseline-characteristics-and-response-to-risedronate-treatment-for-osteoporosis-data-from-three-japanese-phase-iii-trials
#9
T Mawatari, R Muraoka, Y Iwamoto
: We evaluated the influence of baseline age, bone mineral density (BMD), and serum levels of vitamin D on the response to risedronate treatment. Risedronate consistently increased BMD, but our results suggest vitamin D supplementation may be necessary to achieve optimal treatment effect. Furthermore, early intervention may help prevent bone fractures. INTRODUCTION: We aimed to investigate the influence of baseline age, BMD, and vitamin D insufficiency on the response to risedronate treatment...
November 30, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27862203/production-quality-control-and-determination-of-human-absorbed-dose-of-no-carrier-added-177-lu-risedronate-for-bone-pain-palliation-therapy
#10
Nafise Salek, Mohsen Mehrabi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mostafa Erfani, Sara Vosoghi, Mohammad Ghannadi Maragheh, Mojtaba Shamsaei
In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) (177) Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy β(-) emitter, (177) Lu (T½  = 6.7 days, Eβmax  = 497 keV), has been considered as a potential agent for development of bone-seeking radiopharmaceuticals. Because the specific activity of the radiolabeled carrier molecules should be high, the NCA radionuclides have an effective role in nuclear medicine...
November 15, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27852903/effects-of-teriparatide-compared-with-risedronate-on-recovery-after-pertrochanteric-hip-fracture-results-of-a-randomized-active-controlled-double-blind-clinical-trial-at-26-weeks
#11
Per Aspenberg, Jorge Malouf, Umberto Tarantino, Pedro A García-Hernández, Costantino Corradini, Søren Overgaard, Jan J Stepan, Lars Borris, Eric Lespessailles, Frede Frihagen, Kyriakos Papavasiliou, Helmut Petto, José Ramón Caeiro, Fernando Marin
BACKGROUND: Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after pertrochanteric hip fractures. METHODS: The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2). The main inclusion criteria were a bone mineral density T-score of ≤-2...
November 16, 2016: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/27801641/a-systematic-review-and-economic-evaluation-of-bisphosphonates-for-the-prevention-of-fragility-fractures
#12
Sarah Davis, Marrissa Martyn-St James, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson, Mark Strong, Peter Selby, Neil Gittoes
BACKGROUND: Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. OBJECTIVES: To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid (Fosamax(®) and Fosamax(®) Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel(®) and Actonel Once a Week(®), Warner Chilcott UK Ltd), ibandronic acid (Bonviva(®), Roche Products Ltd) and zoledronic acid (Aclasta(®), Novartis Pharmaceuticals UK Ltd)] for the prevention of fragility fracture and to assess their cost-effectiveness at varying levels of fracture risk...
October 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27789081/use-of-drugs-against-osteoporosis-in-the-baltic-countries-during-2010-2014
#13
Ott Laius, Katre Maasalu, Sulev Kõks, Aare Märtson
BACKGROUND AND OBJECTIVE: Osteoporosis is a major health threat nowadays. Aging of the population and changes in peoples' lifestyle result in a constant increase in the number of fractures all over the world. Our study aimed at describing the drug utilization pattern and choice of active substances of antiosteoporotic medicines in the Baltic countries. MATERIALS AND METHODS: Sales data of the antiosteoporotic medicines was obtained from the internet. These are available on the website of medicines regulatory agencies...
2016: Medicina
https://www.readbyqxmd.com/read/27766688/effects-of-bisphosphonates-on-mandibular-condyle-of-ovariectomized-osteoporotic-rats-using-micro-ct-and-histomorphometric-analysis
#14
Liting Jiang, Xing Shen, Li Wei, Qi Zhou, Yiming Gao
OBJECTIVE: To evaluate microarchitectural changes in condylar cartilage and associated subchondral bone after bisphosphonates treatment using an ovariectomized (OVX) osteoporosis rat model. METHODS: Thirty six-month-old female Sprague-Dawley rats were randomly divided into sham, OVX, and risedronate (RIS)-treated groups. Both OVX and RIS groups received bilateral ovariectomy. OVX group was treated subcutaneously with saline, whereas RIS group received risedronate treatment (2...
October 21, 2016: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/27766368/anti-osteoporotic-treatments-in-france-initiation-persistence-and-switches-over-6%C3%A2-years-of-follow-up
#15
M Belhassen, C B Confavreux, B Cortet, L Lamezec, M Ginoux, E Van Ganse
: Limited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006-2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistence with anti-osteoporotic treatment was low, with high proportions of treatment discontinuations and switches. INTRODUCTION: This epidemiological, longitudinal study described first-line treatment initiation, persistence, switches to second-line treatment, and medical care consumption in osteoporotic patients in France during the 2007-2013 period...
October 20, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27747517/comparative-efficacy-of-bisphosphonates-to-prevent-fracture-in-men-with-osteoporosis-a-systematic-review-with-network-meta-analyses
#16
Junwen Zhou, Tiansheng Wang, Xilan Zhao, Donald R Miller, Suodi Zhai
INTRODUCTION: Osteoporosis is an under-recognized problem threatening men. Bisphosphonates are the main treatment but their comparative efficacy is unclear for men with osteoporosis. Therefore, we performed this systematic review with network meta-analyses to summarize the evidence of comparative efficacy of bisphosphonates in men with osteoporosis. METHODS: We completed network meta-analyses with a frequentist model to compare the efficacy of different bisphosphonates...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27746441/bone-histology-of-two-cases-with-osteomalacia-related-to-low-dose-adefovir
#17
Rikako Hiramatsu, Yoshifumi Ubara, Naoki Sawa, Eiko Hasegawa, Masahiro Kawada, Aya Imafuku, Keiichi Sumida, Junichi Hoshino, Kenmei Takaichi
We performed a bone histomorphometric analysis in two patients demonstrating Fanconi syndrome with hypophosphatemia, adefovir-related bone disease and chronic hepatitis B infection. Both patients had osteomalacia, but showed two different histological patterns. The osteoid volume of the patient without risedronate increased with [(osteoid volume/ bone volume)×100=18.6%]. However, the osteoid volume of the patient receiving risedronate without vitamin D analogue showed a greater increase of 53.8%. In both patients bone pain and hypophosphatemia subsided soon after the discontinuation of adefovir and the administration of phosphate derivative...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27725317/timing-of-dental-development-in-osteogenesis-imperfecta-patients-with-and-without-bisphosphonate-treatment
#18
Ilkka Vuorimies, Heidi Arponen, Helena Valta, Outi Tiesalo, Marja Ekholm, Helena Ranta, Marjut Evälahti, Outi Mäkitie, Janna Waltimo-Sirén
Bisphosphonates have established their role as medical therapy for pediatric osteogenesis imperfecta (OI) patients. Since bisphosphonates have also been shown to delay tooth development in animal models, we aimed to assess whether the medication has a similar effect on children with OI. In this cross-sectional study, bisphosphonate-treated OI patients of whom dental panoramic tomograph was taken between 3 and 16years of age formed the study group. The patients, 22 in total, had been treated with pamidronate, zoledronic acid or risedronate for at least one year before the radiography...
January 2017: Bone
https://www.readbyqxmd.com/read/27723270/theranostic-bioabsorbable-bone-fixation-plate-with-drug-layered-double-hydroxide-nanohybrids
#19
Myung Hun Kim, Woojune Hur, Goeun Choi, Hye Sook Min, Tae Hyun Choi, Young Bin Choy, Jin-Ho Choy
A bioabsorbable polymeric bone plate enabled with both diagnostic and therapeutic functionalities (radiopacity and sustained drug release, respectively) is proposed. To this end, a drug-inorganic nanohybrid (RS-LDH) is examined as a theranostic agent by intercalating an anti-resorptive bone remodeling drug, risedronate (RS) into a layered double hydroxide (LDH) via an ion-exchange reaction. The RS-LDH is prepared as a sheet with a biodegradable polymer, poly(lactic-co-glycolic acid), and is then attached onto the clinically approved bioabsorbable bone plate to produce the theranostic plate...
November 2016: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/27683176/oral-bisphosphonates-and-improved-survival-of-breast-cancer
#20
Gad Rennert, Mila Pinchev, Naomi Gronich, Walid Saliba, Anath Flugelman, Idit Lavi, Hadassah Goldberg, Georgeta Fried, Mariana Steiner, Arie Bitterman, Keren Landsman, Hedy S Rennert
PURPOSE: Bisphosphonates are used for treatment or prevention of osteoporosis and of bone metastases. The use of oral bisphosphonates was suggested to be associated with reduced risk of developing breast cancer, and their positive influence on breast cancer survival was only demonstrated with third-generation bisphosphonates. We studied the association of use of oral bisphosphonates after breast cancer diagnosis on overall and breast cancer survival. EXPERIMENTAL DESIGN: A nested case-control analysis was performed using data from the population-based Breast Cancer in Northern Israel Study (BCINIS)...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
27345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"